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Abstract
Background—Attrition along the HIV care continuum slows gains in mitigating the South 
African HIV epidemic. Understanding population-level gaps in HIV identification, linkage, 
retention in care and viral suppression is critical to target programming.
Methods—We conducted a population-based household survey, HIV rapid testing, point-of-care 
CD4 testing, and viral load measurement from dried blood spots (DBS) using multi-stage cluster 
sampling in two sub-districts of North West Province from January–March, 2014. We used 
weighting and multiple imputation of missing data to estimate HIV prevalence, undiagnosed 
infection, linkage and retention in care, medication adherence, and viral suppression.
Results—We sampled 1044 respondents ages 18–49. HIV prevalence was 20.0% (95% CI: 13.7–
26.2) for men and 26.7% (95%CI: 22.1–31.4) for women. Among those HIV-positive, 48.4% of 
men and 75.7% of women were aware of their serostatus; 44.0% of men and 74.8% of women 
reported ever linking to HIV care; 33.1% of men and 58.4% of women were retained in care; and 
21.6% of men and 50.0% of women had DBS viral loads < 5000 copies/mL. Among those already 
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linked to care, 81.7% on ART and 56.0% of those not on ART were retained in care and 51.8% 
currently retained in care on ART had viral loads < 5000 copies/mL.
Conclusions—Despite expanded treatment in South Africa, attrition along the continuum of 
HIV care is slowing prevention progress. Improved detection is critically needed, particularly 
among men. Reported linkage and retention is reasonable for those on ART, however failure to 
achieve viral suppression is worrisome.
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Background
South Africa has the largest HIV antiretroviral treatment (ART) program in the world[1], 
including decentralized ART distribution from primary health clinics and expanded ART 
eligibility[2, 3]. Despite notable progress, there are an estimated 200,000 AIDS-related 
deaths each year[4] and only half of those qualifying for ART are currently receiving 
treatment, which is provided free of charge through the public health system[5]. The 
‘cascade’ of attrition along the HIV care continuum from diagnosis of infection through 
viral suppression[6, 7] in South Africa must be characterized in order to target programming 
and improve the proportion of people who know their status, engage in care, initiate and 
maintain treatment, and achieve viral suppression to stem further transmission[8–10].
Currently, there are limited data providing a comprehensive characterization of the HIV care 
continuum in South Africa. National sero-prevalence data from 2012 indicated that while 
65.0% of the population had ever been tested for HIV, only 37.8% of HIV-positive men and 
55.0% of HIV-positive women were aware of their HIV status[11]. Available data on linkage 
to care and retention following HIV diagnosis comes primarily from data on clinical cohorts. 
Systematic reviews of clinical cohort data across sub-Saharan Africa estimate that 59–66% 
of people with known HIV status have been assessed for ART eligibility and of those 
eligible, less than half returned for follow-up care[7, 12]. Patient retention following ART 
initiation is estimated at 75% and 65% across sub-Saharan Africa after one and three years, 
respectively[13, 14]. Finally, little is known about population-based viral suppression rates 
in sub-Saharan Africa. While data from the South African National Health Laboratory 
Service (NHLS) indicate that approximately 75–80% of ART-initiated patients achieve viral 
suppression, only 40% of ART patients have viral load data available[15].
Population-based data are scarce but extremely important to understand not only where 
attrition occurs but also to estimate the complete population burden of disease and the gaps 
in engagement in clinical care among all people living with HIV (PLWH). We conducted a 
population-based survey to characterize the HIV care continuum in a rural district of North 
West Province, South Africa, an area of the country with substantial burden of disease and 
little available data.
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Methods
Study Setting
Data were collected from January–March 2014 in Lekwa-Teemane and Greater Taung sub-
districts of North West Province, Republic of South Africa. The area is largely rural, with 
over 46.0% of the population living in poverty, compared to a national average of 
39.9%[16]. The province has the fourth highest HIV prevalence in South Africa, estimated 
at 20.3% among adults 15–49 years[11] and 29.7% in the antenatal population [17].
Sampling and Recruitment
We employed multi-stage cluster sampling. Twenty-three enumeration areas (EAs) in each 
sub-district were selected proportionate to size by Statistics South Africa (StatsSA) using 
2011 census data. The sampling frame was developed in September 2013 through 
enumeration of dwelling units (DU) in each EA; fieldworkers recorded the names, ages and 
sex of DU residents. According to census criteria, residence was defined as sleeping in the 
DU an average of four or more nights per week. StatsSA then randomly selected 36 
inhabited DUs from each EA (1561 DUs in total) for inclusion in the sample and randomly 
selected one adult (18–49 years) per DU for participation. When more than one DU resident 
met eligibility criteria (58% of DUs), a second individual was listed as a replacement. 
Replacement household members were only approached if the first participant was no longer 
eligible.
Local, trained fieldworkers approached each assigned DU up to five times to locate the 
selected individual for study participation. Eligibility criteria included being 18–49 years, 
residing in the home, and able to provide consent (not visibly high, drunk, or with a 
discernable cognitive impairment). When a participant was located, fieldworkers confirmed 
eligibility for the study, obtained written informed consent, and conducted a survey by 
computer-assisted personal interviewing (CAPI) in a private location at the participant’s 
home in the participant’s language of choice (English, Xhosa, Afrikaans, or Setswana). The 
survey included questions on demographic characteristics, HIV testing history, health 
services utilization, and health behaviors.
HIV and CD4 T-cell testing and dried blood spot (DBS) collection
Following the survey, point-of-care HIV rapid antibody testing and pre-and post-test 
counseling were performed by trained community health workers (CHWs). HIV serostatus 
was determined by HIV-1/2 antibody rapid testing using the Alere Determine HIV-1/2 rapid 
test with finger-stick capillary blood (Alere, Bedfordview, South Africa), and, if reactive or 
indeterminate, confirmed using the First Response HIV 1–2.0 Rapid Whole Blood Test 
(Premier Medical Corporation Ltd, Daman, India). Participants testing positive or 
indeterminate were offered point-of-care CD4 testing using the Alere Pima™ CD4 analyzer 
(Waltham, MA, USA) using 25 μl of capillary blood, following the manufacturer’s 
instructions. The participant was provided with the test result, counseled on the result’s 
meaning, and referred for care at the local health care facility if needed. Participants with 
HIV-positive or indeterminate results were asked to provide finger-prick blood for dried 
blood spots (DBS) using a Munktell filter card (Ahlstrom Munktell, Helsinki, Finland) for 
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viral load testing. Participants who declined HIV rapid testing in their home were also asked 
to provide blood for DBS for laboratory HIV diagnosis (serology: ELISA confirmed with 
Western blot) and viral load testing and offered a study number to call for the results. DBS 
cards were dried, stored under desiccant at ambient temperature, transported to the testing 
laboratory within six days of collection, and stored at −70°C. Viral load testing was 
performed using the COBAS AmpliPrep for sample preparation and COBAS TaqMan HIV-1 
2.0 test (Roche Applied Science, Pleasanton CA, USA; lower limit of quantification 400 
copies/mL).
Written informed consent was gained for each study procedure; the survey was the only 
required component. Participants were compensated for their time with an airtime voucher 
worth approximately $5 USD following completion of all consented procedures. Study 
procedures were pilot tested in a neighboring sub-district prior to data collection, including a 
quality assurance program for measurement of viral load using DBS [18]. The protocol was 
approved by the Committee for Human Research at the University of California, San 
Francisco; the Human Subjects Division at University of Washington; the Human Sciences 
Research Council Research Ethics Committee in South Africa; the Policy, Planning, 
Research, Monitoring and Evaluation Committee for the North West Provincial Department 
of Health; and the CDC’s Center for Global Health, Human Research Protection.
Measures
Elements of the HIV Care Continuum were defined as follows:
• Undiagnosed or newly diagnosed: HIV-positive participants with no 
reported prior testing or a previous negative test.
• Linked to care: reported ever seeing a nurse or doctor for HIV care.
– Ideal linkage: saw a care provider and completed CD4 
testing within three months of diagnosis.
• Retained in care:
– Participants clinically designated as ART-eligible: reported 
being currently on ART and seeing an HIV care provider 
every three months in the past year[3].
– Participants not yet qualifying for ART: reporting seeing a 
care provider and receiving CD4 testing in the past 
year[19].
• ART adherent: reported taking greater than 90% of their prescribed 
antiretroviral medication in the past month with no lapse of seven or more 
days within the past year[20–22].
• Viral suppression: viral load of <5000 copies/mL. We used this 
conservative threshold as there is no definitive cut-point using DBS[23]. 
We also examined thresholds of <1000 and <3000 copies/mL.
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Prior HIV testing behavior was self-reported. Measured CD4 counts among those 
individuals identified by HIV rapid test as positive were dichotomized at 350 cells/μL, 
reflecting the 2013 South African ART guidelines which were in effect during the data 
collection period[24].
Analysis
All analyses were weighted to account for sample design. Weights were created using the 
inverse probability of selection at each stage (EA, DU and person) and adjusted for non-
response to reflect the municipality, age group and sex distributions within the target 
population [25].
We calculated weighted sample sizes, proportions and 95% confidence intervals (CIs) to 
describe overall and sex-specific participant demographic characteristics, HIV testing, 
prevalence and HIV care engagement. Care continuum outcomes were estimated and 
presented in two ways: 1) among the complete HIV-positive population, in order to provide a 
comprehensive vision of the care continuum in this population-based sample, and 2) 
conditionally, including those previously diagnosed with HIV, with each step in the 
continuum dependent on achieving the previous step, in order to enable comparison with 
clinical cohort data. To evaluate sex-specific differences in the HIV care continuum, we 
estimated chi-square statistics using the second-order Rao and Scott correction for bivariate 
analyses [26], F statistics for age group differences, and generalized linear regression 
modeling (glm). HIV prevalence, ART eligibility and DBS (viral load) results were adjusted 
using multiple imputation to account for non-participation or missing data (see 
Supplemental Digital Content). All analyses were performed using Stata 12 (StataCorp, 
College Station, TX, USA).
Results
Sample Characteristics
Forty-six EAs were visited for enumeration (Figure 1). Three EAs were excluded as 
fieldworkers were not granted access to the areas. Of the remaining 1,527 DUs, 98.5% were 
approached during seven weeks of recruitment. Contact was made at 91.7% of DUs, 
yielding 1,146 eligible individuals, of whom 1048 (76.0% of contacted DUs; 91.0% of 
eligible participants) consented to take part in the study. Four individuals were incorrectly 
recruited, resulting in a total analytic sample of 1,044. The most common reasons for 
ineligibility were no longer residing in the DU (85.4%) and being unable to provide consent 
(6.0%). Overall, those who were not located, not eligible, or declined participation were 
more likely to be male (51.6%) than female (48.4%).
The final weighted sample reflects the gender and age distribution of the sub-districts (Table 
1). Almost all participants were South African citizens or permanent residents (99.4%) and 
just over half (53.9%) were employed in the past year. Two-thirds had not completed 
secondary school and about one-quarter of the sample experienced household food 
insecurity, defined as having gone to bed hungry some to most of the time in the past month.
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HIV Prevalence, CD4, and HIV Testing
Among 745 respondents undergoing either rapid HIV testing or HIV testing using DBS 
(71.7% of the sample), 183 individuals tested positive. An additional 35 respondents who 
declined testing reported positive serostatus, resulting in a total of 218 HIV-positive 
participants. Point-of-care CD4 tests were performed on 158 (94.1%) of participants with an 
HIV-positive rapid test result. DBS were collected from 157 (93.5%) participants who tested 
HIV-positive or indeterminate in the field, 51 participants who declined rapid testing, and 1 
was collected from an HIV-negative participant in error, resulting in a total of 209 DBS 
collected.
Overall 20.0% (95% CI: 13.7–26.2) of men and 26.7% (95% CI: 22.1–31.4) of women were 
HIV positive (Table 2); prevalence was higher among females than males in every age group 
(Table 2). Males’ prevalence increased with age, peaking at 40–49 years; females’ 
prevalence peaked at 30–39 years. While 68.9% of men (95% CI: 61.8–75.1) and 89.2% of 
women (95% CI: 84.2–92.7) reported having tested previously, there were a substantial 
number of new HIV diagnoses, particularly among men. Among those newly diagnosed, 
approximately one-third of women and men reported having tested negative in the previous 
12 months; one-third of men reported having never tested (Table 2). CD4 cell count varied 
significantly by sex; CD4 counts were lower for men; this was true among both newly 
diagnosed men and those who already knew their serostatus (data not shown).
HIV Continuum of Care
Population-based: among all HIV-positive people—There was major attrition along 
the HIV continuum of care for the full HIV-positive population, with the most significant 
drop occurring at the gateway to the care continuum: testing, particularly for men (Figure 2; 
Table S1). Over half (51.6%, 95% CI: 39.5–63.5) of men and one-quarter (24.3%, 95% CI: 
14.9–36.9) of women identified as HIV-positive were previously unaware of their serostatus. 
The proportion of those who eventually linked to care was similar to the proportion of those 
previously diagnosed, suggesting that those who are aware of their HIV-positive status will 
eventually seek care. However, we observed additional attrition associated with retention, 
treatment and viral suppression. Only 33.1% (95% CI: 21.4–47.3) of HIV-positive men and 
58.4% (95% CI: 49.2–67.1) of women were retained in care, of whom the majority had been 
initiated on ART (Figure 2 shaded area represents the proportion of those retained classified 
as pre-ART). While 33.1% (95% CI: 21.8–46.8) and 53.5% (95% CI: 42.6–64.1) of HIV-
positive men and women reported adherence to medication, only 21.6% (95% CI: 7.6–35.7) 
and 50.0% (95% CI: 39.4–60.7) of HIV-positive men and women respectively had attained 
viral suppression, using a conservative threshold of 5000 copies/mL (Figure 2).
Conditional Cascade: among those achieving each prior step—Next, we 
examined attrition across the care continuum conditioning on each previous step, among 
those who already knew their positive HIV status (Figure 3; Table S2). The majority of 
PLWH, 98.8% of women (95% CI: 96.0–99.6) and 90.8% of men (95% CI: 80.3–96.0) were 
ever linked to care, though less than 60% linked to care three months of diagnosis (ideal 
linkage). Among those who ever linked to care, 75.2% (95% CI: 52.0–89.5) of men and 
78.1% (95% CI: 68.1–85.7) of women were retained in care; retention being higher among 
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those ART-eligible. The vast majority of men (97.2%, 95% CI: 80.7–99.7) and women 
(91.6%, 95% CI: 80.3–96.7) retained in care on ART reported adhering to their medication, 
however, only 28.8% (95% CI 4.7–52.9) of men and 59.7% (95% CI: 43.3–76.1) of women 
achieved viral load below 5000 copies/mL. We utilized a higher threshold for determining 
viral suppression with DBS[23] than that which is recommended for plasma. Thus, 
population viral suppression may be overestimated. Using cut-offs of <1000 and < 3000 
copies/mL, respectively, 25.7% (95% 12.5–39.0) and 40.1% (95% CI: 24.4–55.6) of the 
population retained on ART would be classified as virally suppressed(Table S2). Of note, 
fewer than 50% of participants who should have had a viral load conducted (all those on 
ART for at least 6 months), reported past viral load testing.
Discussion
These results provide a comprehensive picture of engagement in HIV care from diagnosis to 
viral suppression in a geographic area with little previous research but extremely high 
burden of disease. Based on the full HIV-positive population, it is quite clear that the greatest 
gap in engagement occurs at HIV diagnosis, indicating a critical need for improving case 
detection, particularly among men. Less than half of HIV-positive men and three-quarters of 
HIV-positive women were aware of their serostatus prior to our survey. Previous population-
based seroprevalence data point to similar rates of reported HIV testing and an even higher 
proportion of undiagnosed infections [11, 27], particularly among men [27–29]. HIV 
prevalence in our sample was also similar to that reported for adults in the North West 
Province in the 2012 national survey (20.3%) [11] and for women in the national antenatal 
survey (29.7%) [17]. With continued losses along the continuum of care at linkage, 
retention, and ART adherence, a resulting 50% of women and 21% of men living with HIV 
in the region are virally suppressed under a best case scenario (using a liberal definition of 
suppression). This portends continued high rates of transmission in the area unless uptake of 
testing and treatment initiation improves rapidly and rates of viral suppression are greatly 
improved.
We also assessed the conditional continuum of care, beginning with those aware of their 
HIV-positive status, to compare our findings to data from clinical cohorts. We found 
remarkably similar patterns: among survey participants who were previously aware of their 
positive serostatus, almost all reported having seen a care provider for HIV, though only 
54% reported being assessed for ART eligibility within three months of diagnosis[32, 33]. 
This estimate, though based on self-report, is consistent with data from South African 
clinical cohorts, which have found that between 50% and 70% of HIV-positive patients 
undergo CD4 staging within three months[12, 19, 34, 35]. Our findings regarding retention 
in care also correspond with estimates from South African clinical cohorts, despite different 
methods of measurement. Unlike studies that monitor retention within a clinic, we assessed 
frequency of care without detailed case history tied to a particular clinic. For patients who 
were known to be eligible for ART, 81.7% reported remaining on ART and receiving care at 
least every three months in the past year (as clinics provide ART for 1–3 month increments). 
South African clinical cohorts have documented retention among ART-initiated patients of 
75% at one year[19], 81% remaining on treatment for two years[36], and data from the 
National Health Indicators Report indicate that 82% of initiated patients remained on 
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treatment at three years (among those reported into the national system)[15]. Pre-ART 
retention, also referred to as stage 2 retention[32], in our study was low: 68% of women and 
no men were retained in this stage (due to no men being previously diagnosed prior to 
treatment eligibility, an indication that men do not seek testing until they are already ill). 
Studies from Cape Town, Johannesburg, and Kwa-Zulu Natal similarly documented that 45–
57% of those not ART eligible returned for a subsequent CD4 test in approximate one-year 
time frames, with men being less likely than women to return for subsequent testing[19, 34, 
37].
Our findings demonstrate high reported adherence, but low rates of viral suppression, 
indicating a potential bias in self-reported adherence data, which could be due to social 
desirability bias or over-reporting of medication adherence, as well as medication failure. 
While the effect of social desirability bias would likely over-estimate the proportion of those 
‘adherent’ to care, ART adherence is not always over-reported. While pre-exposure 
prophylaxis (PrEP) clinical trial data among women in Africa indicate extreme over-
reporting of medication adherence[38], instances of under-reporting usage of antiretrovirals 
in large trials have also been documented[39]. A recent population-based HIV survey in 
South Africa, found high agreement between self-reported ART intake and blood-tested 
ART exposure (κ = 91.9%). Self-report and blood test discrepancies were demonstrated in 
both directions, such that just over 7% of those reporting ART intake had negative blood 
tests and similar numbers reporting no ART intake had positive blood tests for ART[40]. 
Further analysis of the DBS samples should shed light on drug exposure.
We used a conservative threshold for defining viral suppression due to the sample matrix 
utilized, as cellular HIV DNA contributes to copy number when using whole blood instead 
of blood plasma samples[23]. By utilizing 5,000 copies/mL as a threshold we run the risk of 
overestimating viral suppression. If we lower the threshold to 3,000 copies/mL or even to 
1,000 copies, viral suppression among all those on ART is estimated at 40.1% and 25.7% as 
opposed to 51.8%. Viral suppression in this study is below national targets and estimates 
from other recent population-based studies[41], but aligns with estimates based on 
population-level projections from national data[42]. Data from the NHLS suggests viral 
suppression (defining viral suppression as <400 copies/mL plasma) ranges from 52–75% for 
North West Province, depending on the district[15]. However, NHLS viral load information 
is available for less than half of ART-patients; which is consistent with reported rates of viral 
load testing in our sample. This may indicate that treatment failure is not being properly 
monitored and could lead to high rates of HIV-1 drug resistance in this rural population. 
Additionally, food insecurity, which was prevalent in this sample, has been shown to be an 
independent predictor of incomplete viral suppression after adjustment for ART 
adherence[43].
Our data has several limitations, as well as strengths. First, linkage, retention, and adherence 
is based on self-report and not linked to clinic records; participants may not recall dates 
and/or over-report clinic attendance and adherence. Second, those who are in care are more 
likely to survive and therefore more likely to be included in our estimates; this survivor bias 
may lead to inflated estimates of engagement in care. However, our findings on the 
proportion of those linked to and retained in care are quite similar to findings from clinical 
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cohorts utilizing documented treatment history and accounting for death. Third, our sample 
cannot account for populations who are highly mobile, unlikely to be included in survey 
data, and more likely to drop out of care[44]. Both in and out migration in North West 
Province is extremely common[45]; in our data, approximately 13% of the original sample 
were no longer at the residence only six months after the area was enumerated. One strength 
of these data is the potential to capture more inclusive measures of engagement to care, in 
that our estimates of linkage and retention are not impacted by mobility between clinics or 
erroneous classification of patients as out of care when they are, in fact, deceased[12]. 
Further, it should be noted that prevalence may be underestimated in our data, despite 
adjustments for non-response, as HIV-positive individuals are more likely to refuse 
testing[30, 31].
Conclusion
Increasing ART coverage can significantly lower the risk of new HIV infections in South 
Africa[46]. However, treatment expansion will only extend prevention gains if infected 
individuals are identified early in their HIV disease, enter into care rapidly, remain in care, 
adhere to ART, and achieve viral suppression. These population-based data provide a 
comprehensive picture of the HIV care continuum in the North West Province and should be 
utilized to inform targeted programming. While attrition occurs along all steps of the 
cascade, the most urgent need is for improved HIV detection, particularly among men. 
Evidence-based, male-targeted programming, including programs that address male norms 
that dissuade care seeking and work- and community-based programming outside of the 
clinic environment, is sorely needed to improve testing uptake, frequency, and early linkage 
to care. The low proportion of those achieving viral suppression also requires urgent 
attention. At present population viral load is still too elevated to expect treatment as 
prevention to achieve its potential impact in this region. Future research to understand the 
discrepancies between reported adherence and viral suppression is warranted.
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Figure 1. 
Participant recruitment, enrollment, and data collection, North West Province, South Africa
*HIV Rapid Test (n=694) or DBS only (n=51); 3 individuals consented but did not test as 
fieldwork team was unable to locate them when they returned for scheduled testing.
τEnrolled replacement though original selection was eligible and had declined.
σ86.1% (n=899) target individual and 13.9% (n=145) replacement household member.
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Figure 2. 
Continuum of HIV Care among all those HIV-positive, North West Province, South Africa
Denominators include all HIV-positive participants and are not conditional upon completing 
any prior step of the continuum of care.
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Figure 3. 
Conditional Continuum of HIV Care, North West Province, South Africa
Denominators include all HIV-positive participants that were previously aware of their status 
and are conditional upon completing each prior step of the continuum of care.
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Table 1
Participant demographic characteristics, North West Province, South Africa, 2014.
Participant Characteristics wgt n*=92,507
wgt %* 95% CI
Sex
 Male 47.0 41.8–52.2
 Female 53.0 47.8–58.2
Age group
 18–29 Years 49.0 45.2–52.8
 30–39 Years 28.0 25.0–31.3
 40–49 Years 23.0 20.1–26.1
South African citizen/permanent resident 99.4 98.6–99.8
Employed past 12 months 53.9 48.8–59.0
Marital status
 Married/living with partner 25.8 21.5–30.7
 Single/In relationship 70.3 65.5–74.8
 Single (separated/divorced) 2.1 1.3–3.4
 Single (widowed) 1.7 1.1–2.8
Educational attainment
 Primary or less 21.0 17.0–25.5
 Some secondary 43.7 38.5–48.9
 Completed secondary 27.6 23.4–32.3
 College/University or technikon 7.7 4.4–13.4
Food insecurity past month 25.7 20.7–31.3
*Weights account for sampling, non-response, and age/gender of target population.
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